Relationship between venous and arterial thrombosis: A review of the literature from a causal perspective

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 8, 2011, Pages 885-896

  Lijfering, Willem M ^a   Flinterman, Linda E ^a   Vandenbroucke, Jan P ^a   Rosendaal, Frits R ^a   Cannegieter, Suzanne C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

arterial thrombosis; atherosclerosis; epidemiology; vascular diseases; Venous thrombosis

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTERY THROMBOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAUSAL ATTRIBUTION; CONFOUNDING VARIABLE; DISEASE ASSOCIATION; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; VEIN THROMBOSIS;

ATHEROSCLEROSIS; FEMALE; HUMANS; MALE; RISK FACTORS; THROMBOSIS; VENOUS THROMBOSIS;

EID: 84555208710     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1297367     Document Type: Review

References (121)

1. Fauci A S., Braunwald E, Kasper D L. et al. Harrison's Principles of Internal Medicine. 17th ed. New York, NY McGraw-Hill 2008
2. Squizzato A, Galli M, Romualdi E et al. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur Heart J 2010 31 10 1248-1256
3. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen P W. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008 117 1 93-102 (Pubitemid 350301144)
4. Sørensen H T., Horvath-Puho E, Søgaard K K. et al. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based casecontrol study. J Thromb Haemost 2009 7 4 521-528
5. Sørensen H T., Horvath-Puho E, Pedersen L, Baron J A., Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007 370 9601 1773-1779 (Pubitemid 350137491)
6. Becattini C, Agnelli G, Prandoni P et al. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 2005 26 1 77-83 (Pubitemid 40221127)
7. Klok F A., Mos I C., Broek L et al. Risk of arterial cardiovascular events in patients after pulmonary embolism. Blood 2009 114 8 1484-1488
8. Prandoni P, Bilora F, Marchiori A et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003 348 15 1435-1441 (Pubitemid 36407172)
9. van der Hagen P B., Folsom A R., Jenny N S. et al. Subclinical atherosclerosis and the risk of future venous thrombosis in the Cardiovascular Health Study. J Thromb Haemost 2006 4 9 1903-1908 (Pubitemid 44226766)
10. Reich L M., Folsom A R., Key N S. et al. Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J Thromb Haemost 2006 4 9 1909-1913 (Pubitemid 44226767)
11. Lijfering W M., Rosendaal F R., Cannegieter S C. Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol 2010 149 6 824-833
12. Collins R, MacMahon S, Flather M et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 1996 313 7058 652-659 (Pubitemid 26300601)
13. Bath P M., Iddenden R, Bath F J. Low-molecular-weight heparins and heparinoids in acute ischemic stroke: a meta-analysis of randomized controlled trials. Stroke 2000 31 7 1770-1778 (Pubitemid 30437536)
14. Prandoni P. Venous thromboembolism and atherosclerosis: is there a link? J Thromb Haemost 2007 5 Suppl 1 270-275 (Pubitemid 46958842)
15. Meade T W., Mellows S, Brozovic M et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986 2 8506 533-537 (Pubitemid 16054632)
16. Folsom A R., Rosamond W D., Shahar E et al, The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Prospective study of markers of hemostatic function with risk of ischemic stroke. Circulation 1999 100 7 736-742 (Pubitemid 29383644)
17. De Buyzere M, Philippé J, Duprez D, Baele G, Clement D L. Coagulation system activation and increase of D-dimer levels in peripheral arterial occlusive disease. Am J Hematol 1993 43 2 91-94 (Pubitemid 23144264)
18. Becattini C, Vedovati M C., Ageno W, Dentali F, Agnelli G. Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis. J Thromb Haemost 2010 8 5 891-897
19. Hansson G K. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost 2009 7 Suppl 1 328-331
20. Borissoff J I., Heeneman S, Kilinç E et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 2010 122 8 821-830
21. Roumen-Klappe E M., den Heijer M, van Uum S H., van der Ven-Jongekrijg J, van der Graaf F, Wollersheim H. Inflammatory response in the acute phase of deep vein thrombosis. J Vasc Surg 2002 35 4 701-706
22. Roumen-Klappe E M., Janssen M C., Van Rossum J et al. Inflammation in deep vein thrombosis and the development of post-thrombotic syndrome: a prospective study. J Thromb Haemost 2009 7 4 582-587
23. Price P A., Faus S A., Williamson M K. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998 18 9 1400-1407 (Pubitemid 28421877)
24. Rennenberg R J., van Varik B J., Schurgers L J. et al. Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans. Blood 2010 115 24 5121-5123
25. Handke M, Harloff A, Bode C, Geibel A. Patent foramen ovale and cryptogenic stroke: a matter of age? Semin Thromb Hemost 2009 35 5 505-514
26. Bova C, Marchiori A, Noto A et al. Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism. A retrospective cohort study. Thromb Haemost 2006 96 2 132-136 (Pubitemid 44219378)
27. Abdollahi M, Cushman M, Rosendaal F R. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003 89 3 493-498 (Pubitemid 36329240)
28. Pomp E R., le Cessie S, Rosendaal F R., Doggen C J. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007 139 2 289-296 (Pubitemid 47493087)
29. Lijfering W M., Christiansen S C., Naess I A. et al. The risk of venous thrombosis related to increase in body mass index is mediated by factor VIII induced APC-resistance. Blood 2009 114 453 (ASH Annual Meeting Abstracts)
30. Bank I, Libourel E J., Middeldorp S et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 2005 3 1 79-84 (Pubitemid 41647118)
31. Faber D R., de Groot P G., Visseren F L. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes Rev 2009 10 5 554-563
32. Darvall K A., Sam R C., Silverman S H., Bradbury A W., Adam D J. Obesity and thrombosis. Eur J Vasc Endovasc Surg 2007 33 2 223-233 (Pubitemid 46076268)
33. Hautanen A. Synthesis and regulation of sex hormone-binding globulin in obesity. Int J Obes Relat Metab Disord 2000 24 Suppl 2 S64-S70 (Pubitemid 30461951)
34. Middeldorp S, Meijers J C., van den Ende A E. et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000 84 1 4-8 (Pubitemid 30433659)
35. Naess I A., Christiansen S C., Romundstad P, Cannegieter S C., Rosendaal F R., Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007 5 4 692-699 (Pubitemid 46563566)
36. Mahmoodi B K., Gansevoort R T., Veeger N J. et al, Prevention of Renal and Vascular End-stage Disease (PREVEND) Study Group. Microalbuminuria and risk of venous thromboembolism. JAMA 2009 301 17 1790-1797
37. Tsai A W., Cushman M, Rosamond W D., Heckbert S R., Polak J F., Folsom A R. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002 162 10 1182-1189 (Pubitemid 34522408)
38. Holst A G., Jensen G, Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation 2010 121 17 1896-1903
39. Heit J A., Leibson C L., Ashrani A A., Petterson T M., Bailey K R., Melton L J. III. Is diabetes mellitus an independent risk factor for venous thromboembolism?: a population-based casecontrol study. Arterioscler Thromb Vasc Biol 2009 29 9 1399-1405
40. Petrauskiene V, Falk M, Waernbaum I, Norberg M, Eriksson J W. The risk of venous thromboembolism is markedly elevated in patients with diabetes. Diabetologia 2005 48 5 1017-1021 (Pubitemid 40767997)
41. Ageno W, Prandoni P, Romualdi E et al. The metabolic syndrome and the risk of venous thrombosis: a casecontrol study. J Thromb Haemost 2006 4 9 1914-1918 (Pubitemid 44226768)
42. Dentali F, Squizzato A, Ageno W. The metabolic syndrome as a risk factor for venous and arterial thrombosis. Semin Thromb Hemost 2009 35 5 451-457
43. Steffen L M., Cushman M, Peacock J M. et al. Metabolic syndrome and risk of venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology. J Thromb Haemost 2009 7 5 746-751
44. Borch K H., Braekkan S K., Mathiesen E B. et al. Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: the Tromsø study. J Thromb Haemost 2009 7 5 739-745
45. Chamberlain A M., Folsom A R., Heckbert S R., Rosamond W D., Cushman M. High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood 2008 112 7 2675-2680
46. Glynn R J., Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. Am J Epidemiol 2005 162 10 975-982 (Pubitemid 41619468)
47. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994 309 6959 901-911
48. Wannamethee S G., Lowe G D., Shaper A G., Rumley A, Lennon L, Whincup P H. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J 2005 26 17 1765-1773 (Pubitemid 41219850)
49. Pomp E R., Rosendaal F R., Doggen C J. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 2008 83 2 97-102
50. Severinsen M T., Kristensen S R., Johnsen S P., Dethlefsen C, Tjønneland A, Overvad K. Smoking and venous thromboembolism: a Danish follow-up study. J Thromb Haemost 2009 7 8 1297-1303
51. Mulder R, van Schouwenburg I M., Mahmoodi B K. et al. Associations between high factor VIII and low free protein S levels with traditional arterial thrombotic risk factors and their risk on arterial thrombosis: results from a retrospective family cohort study. Thromb Res 2010 126 4 e249-e254
52. Doggen C J., Rosendaal F R., Meijers J C. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood 2006 108 13 4045-4051 (Pubitemid 44913273)
53. Folsom A R., Wu K K., Shahar E, Davis C E., The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb 1993 13 12 1829-1836 (Pubitemid 23360570)
54. Ye Z, Liu E H., Higgins J P. et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006 367 9511 651-658 (Pubitemid 43289155)
55. Mahmoodi B K., Brouwer J L., Veeger N J., van der Meer J. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation 2008 118 16 1659-1667
56. Rosendaal F R. Clotting and myocardial infarction: a cycle of insights. J Thromb Haemost 2003 1 4 640-642
57. Rosendaal F R., Varekamp I, Smit C et al. Mortality and causes of death in Dutch haemophiliacs, 1973-86. Br J Haematol 1989 71 1 71-76 (Pubitemid 19047700)
58. Triemstra M, Rosendaal F R., Smit C, Van der Ploeg H M., Briët E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 1995 123 11 823-827
59. Srámek A, Kriek M, Rosendaal F R. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003 362 9381 351-354 (Pubitemid 36945057)
60. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990 323 3 147-152 (Pubitemid 20219942)
61. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984 251 3 351-364
62. Baigent C, Keech A, Kearney P M. et al, Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 366 9493 1267-1278
63. Ramcharan A S., Van Stralen K J., Snoep J D., Mantel-Teeuwisse A K., Rosendaal F R., Doggen C J. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 2009 7 4 514-520
64. Glynn R J., Danielson E, Fonseca F A. et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009 360 18 1851-1861
65. Cushman M. A new indication for statins to prevent venous thromboembolism? Not yet. J Thromb Haemost 2009 7 4 511-513
66. Morishita E, Asakura H, Saito M et al. Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients. Atherosclerosis 2001 154 1 203-212 (Pubitemid 32008582)
67. Musia J, Undas A, Undas R, Brozek J, Szczeklik A. Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels. Thromb Haemost 2001 85 2 221-225 (Pubitemid 32140564)
68. Dangas G, Badimon J J., Smith D A. et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999 33 5 1294-1304
69. Ridker P M., Danielson E, Fonseca F A. et al, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 359 21 2195-2207
70. Piazza G, Goldhaber S Z. Venous thromboembolism and atherothrombosis: an integrated approach. Circulation 2010 121 19 2146-2150
71. Heit J A., Silverstein M D., Mohr D N., Petterson T M., O'Fallon W M., Melton L J. III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based casecontrol study. Arch Intern Med 2000 160 6 809-815 (Pubitemid 30165241)
72. Heit J A., Kobbervig C E., James A H., Petterson T M., Bailey K R., Melton L J. III. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005 143 10 697-706
73. van Hylckama Vlieg A, Helmerhorst F M., Vandenbroucke J P., Doggen C J., Rosendaal F R. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA casecontrol study. BMJ 2009 339 b2921
74. Lidegaard Ø, Løkkegaard E, Svendsen A L., Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009 339 b2890
75. Blom J W., Doggen C J., Osanto S, Rosendaal F R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005 293 6 715-722 (Pubitemid 40216041)
76. Ginsberg J S., Wells P S., Brill-Edwards P et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995 86 10 3685-3691
77. Matta F, Singala R, Yaekoub A Y., Najjar R, Stein P D. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost 2009 101 1 134-138
78. Brouwer J L., Bijl M, Veeger N J., Kluin-Nelemans H C., van der Meer J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004 104 1 143-148 (Pubitemid 38879850)
79. Grainge M J., West J, Card T R. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010 375 9715 657-663
80. van Zaane B, Squizzato A, Huijgen R et al. Increasing levels of free thyroxine as a risk factor for a first venous thrombosis: a casecontrol study. Blood 2010 115 22 4344-4349
81. Lijfering W M., Ten Kate M K., Sprenger H G., van der Meer J. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy. J Thromb Haemost 2006 4 9 1928-1930 (Pubitemid 44226770)
82. Mahmoodi B K., ten Kate M K., Waanders F et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 2008 117 2 224-230
83. Wattanakit K, Cushman M, Stehman-Breen C, Heckbert S R., Folsom A R. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 2008 19 1 135-140
84. Ocak G, Verduijn M, Vossen C Y. et al. Chronic kidney disease stages 1-3 increase the risk of venous thrombosis. J Thromb Haemost 2010 8 11 2428-2435
85. Cannegieter S C., Doggen C J., van Houwelingen H C., Rosendaal F R. Travel-related venous thrombosis: results from a large population-based case control study (MEGA study). PLoS Med 2006 3 8 e307
86. Smeeth L, Cook C, Thomas S, Hall A J., Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006 367 9516 1075-1079
87. Lijfering W M., Brouwer J L., Veeger N J. et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 2009 113 21 5314-5322
88. Rosendaal F R., Koster T, Vandenbroucke J P., Reitsma P H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995 85 6 1504-1508
89. Poort S R., Rosendaal F R., Reitsma P H., Bertina R M. A common genetic variation in the 3-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996 88 10 3698-3703 (Pubitemid 26383091)
90. Jick H, Slone D, Westerholm B et al. Venous thromboembolic disease and ABO blood type. A cooperative study. Lancet 1969 1 7594 539-542
91. Lijfering W M., Mulder R, ten Kate M K., Veeger N J., Mulder A B., van der Meer J. Clinical relevance of decreased free protein S levels: results from a retrospective family cohort study involving 1143 relatives. Blood 2009 113 6 1225-1230
92. Koster T, Blann A D., Briët E, Vandenbroucke J P., Rosendaal F R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995 345 8943 152-155
93. den Heijer M, Koster T, Blom H J. et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996 334 12 759-762 (Pubitemid 26089357)
94. Meltzer M E., Lisman T, Doggen C J., de Groot P G., Rosendaal F R. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med 2008 5 5 e97
95. Folsom A R., Lutsey P L., Astor B C., Cushman M. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost 2009 102 4 615-619
96. Quist-Paulsen P, Naess I A., Cannegieter S C. et al. Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica 2010 95 1 119-125
97. Bots M L., Hoes A W., Koudstaal P J., Hofman A, Grobbee D E. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997 96 5 1432-1437 (Pubitemid 27375333)
98. James A H., Jamison M G., Biswas M S., Brancazio L R., Swamy G K., Myers E R. Acute myocardial infarction in pregnancy: a United States population-based study. Circulation 2006 113 12 1564-1571 (Pubitemid 43739415)
99. Van Den Bosch M A., Kemmeren J M., Tanis B C. et al. The RATIO study: oral contraceptives and the risk of peripheral arterial disease in young women. J Thromb Haemost 2003 1 3 439-444
100. Tanis B C., van den Bosch M A., Kemmeren J M. et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001 345 25 1787-1793
101. Yusuf S, Hawken S, Ounpuu S et al, INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): casecontrol study. Lancet 2004 364 9438 937-952 (Pubitemid 39208455)
102. Sytkowski P A., D'Agostino R B., Belanger A, Kannel W B. Sex and time trends in cardiovascular disease incidence and mortality: the Framingham Heart Study, 1950-1989. Am J Epidemiol 1996 143 4 338-350
103. Teo K K., Ounpuu S, Hawken S et al, INTERHEART Study Investigators. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a casecontrol study. Lancet 2006 368 9536 647-658 (Pubitemid 44223693)
104. Kannel W B. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995 76 9 69C-77C
105. Booth G L., Kapral M K., Fung K, Tu J V. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006 368 9529 29-36 (Pubitemid 43947203)
106. Urbanus R T., Siegerink B, Roest M, Rosendaal F R., de Groot P G., Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a casecontrol study. Lancet Neurol 2009 8 11 998-1005
107. Peters M J., van Halm V P., Voskuyl A E. et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009 61 11 1571-1579
108. Barcat D, Guérin V, Ryman A et al. Thrombophilia and thrombosis in systemic lupus erythematosus: a casecontrol study. Ann Rheum Dis 2003 62 10 1016-1017 (Pubitemid 37159506)
109. Ha C, Magowan S, Accortt N A., Chen J, Stone C D. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol 2009 104 6 1445-1451
110. Flynn R W., Macdonald T M., Jung R T., Morris A D., Leese G P. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab 2006 91 6 2159-2164 (Pubitemid 43854999)
111. Mann J F., Gerstein H C., Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001 134 8 629-636 (Pubitemid 32322240)
112. Gerstein H C., Mann J F., Yi Q et al, HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001 286 4 421-426 (Pubitemid 32681484)
113. Smeeth L, Thomas S L., Hall A J., Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004 351 25 2611-2618 (Pubitemid 39628582)
114. Tanis B, Algra A, van der Graaf Y, Helmerhorst F, Rosendaal F. Procoagulant factors and the risk of myocardial infarction in young women. Eur J Haematol 2006 77 1 67-73 (Pubitemid 43876208)
115. Folsom A R., Rosamond W D., Shahar E et al, The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Prospective study of markers of hemostatic function with risk of ischemic stroke. Circulation 1999 100 7 736-742 (Pubitemid 29383644)
116. Stampfer M J., Malinow M R., Willett W C. et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992 268 7 877-881
117. Loscalzo J. Homocysteine trialsclear outcomes for complex reasons. N Engl J Med 2006 354 15 1629-1632
118. Meltzer M E., Doggen C J., de Groot P G., Rosendaal F R., Lisman T. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. Blood 2010 116 4 529-536
119. Meltzer M E., Doggen C J., de Groot P G., Rosendaal F R., Lisman T. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost 2009 35 5 468-477
120. Snoep J D., Roest M, Barendrecht A D., De Groot P G., Rosendaal F R., Van Der Bom J G. High platelet reactivity is associated with myocardial infarction in premenopausal women: a population-based casecontrol study. J Thromb Haemost 2010 8 5 906-913
121. Kaptoge S, Di Angelantonio E, Lowe G et al, Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010 375 9709 132-140